

New Reports: COVID-19 Derails Progress Against HIV

ZOOM WEBINAR | Tuesday, November 15, 2022 @ 2:30pm ET/1:30pm CT/11:30am PT

Please join the O'Neill Institute for a virtual briefing on how the COVID-19 pandemic has impacted efforts to end the HIV epidemic in America. New evidence illustrates that the pandemic has significantly affected critical indicators, such as access to HIV testing, diagnosis, and treatment and delayed our progress in ending the epidemic.

Date: Tuesday, November 15, 2022

Time: 2:30 - 4:00 PM ET

REGISTER NOW

The conversation will include researchers, policy experts, and community advocates. Panelists will highlight the urgent action needed to get back on track towards ending the HIV epidemic. They will also discuss the findings from a new white paper from Milliman, <u>Study of the Impact of COVID-19 on HIV Testing, Diagnosis and Treatment in the United States</u>, and new report from GLAAD, <u>Invisible People: A Retrospective Report on the Impacts of COVID & HIV in the United States</u>.



Jeffrey S. Crowley, Moderator | Program Director of the Infectious Diseases Initiative, The O'Neill Institute for National & Global Health Law

Jeffrey Crowley directs the O'Neill Institute's work related to HIV, Hepatitis, and other infectious diseases. His career has focused on federal health care policy with an emphasis on Medicaid, Medicare, and issues impacting people with HIV and other people with disabilities. From 2009 to 2011, he was the director of the White House Office of National AIDS Policy (ONAP) and senior advisor on disability policy for President Barack Obama.



Susan Silseth | Consulting Actuary, Milliman

Susan Silseth is a consulting actuary with Milliman's Milwaukee office. She joined the firm in 2011. Susan possesses a mix of consulting and industry practice over her fifteen year tenure. Today, she leads teams to complete strategic analyses in the areas of Medicare Part D and pharmaceutical manufacturer consulting.



Tristan Marra | Head of Research & Reports, GLAAD

Tristan Marra (she/her) is Head of Research & Reports at the GLAAD Media Institute, where she leads new and existing GLAAD research initiatives, analytics and reports, and provides thought leadership that continues to advance GLAAD's core work and mission of accelerating acceptance for the LGBTQ community. Tristan comes to GLAAD with nearly 15 years of research experience, working for media companies including NBCUniversal, The Walt Disney Company, and Paramount. Her background is in studying consumers, brands, and campaign effectiveness across the media landscape.



Dafina Ward, J.D. | Executive Director, Southern AIDS Coalition

Dafina Ward, J.D. is an attorney and non-profit strategist with nearly fifteen years of experience addressing HIV and health equity issues in the southern United States. Working in partnership with a range of advocates—from grassroots leaders to federal decision–makers—she is a trusted voice in regional and national spaces.



Kirk Myers-Hill | Founder and President/CEO, Abounding Prosperity, Inc.

Kirk Myers-Hill is the founder and President/Chief Executive Officer (CEO) of Abounding Prosperity, Inc. The agency's mission is to address health, social and economic disparities among Black men including gay, bisexual and transgender (male- to-female) individuals and their identified families living in Dallas County, Texas.



Kirk Grisham | Associate, The O'Neill Institute for National & Global Health Law

Kirk Grisham is an associate with the Infectious Diseases Initiative at the O'Neill Institute working on HIV treatment and prevention policy and co-leads a policy project on longer-acting HIV treatment and PrEP. Over the past twelve years, Kirk has worked to advance public health through research and advocacy in community-based, academic, and public interest organizations.

About The O'Neill Institute: In bringing together both health and legal fields, the O'Neill Institute reflects the importance of public and private law in health policy analysis.





@oneillinstitute

This webinar is conducted with support from Gilead Sciences, Inc.